4
Clinical Trials associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)A Clinical Study to Evaluate the Safety and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Combination With Toripalimab and Regorafenib in Patients With Liver Metastases From Colorectal Cancer
This is a phase I, open-label clinical study of BioTTT001 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
A Clinical Study to Evaluate the Safety and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Combination With SOX and Toripalimab in Patients With Peritoneal Metastases From Gastric Cancer
This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.
Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients With Malignant Solid Tumors
This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.
100 Clinical Results associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
100 Translational Medicine associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
100 Patents (Medical) associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
100 Deals associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)